Goldfinch Bio instigates Phase 1 trial of GFB-887 for Kidney Disease
Category: #healthcare  By Mateen Dalal  Date: 2019-06-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Goldfinch Bio instigates Phase 1 trial of GFB-887 for Kidney Disease

Goldfinch Bio, Inc., a biotechnology firm developing precision therapies for kidney disease patients, has reportedly started dosing in its Phase 1 clinical trial assessing GFB-887. The firm’s selective and sub-type specific small molecule TRPC5 inhibitor, GFB-887, is being evaluated as a possible treatment for kidney diseases linked with progressive renal dysfunction and proteinuria comprising treatment-resistant minimal change disease (TR-MCD), focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN).

As per trusted sources, the study will evaluate the drug based on tolerability, safety, and pharmacokinetic profile among healthy volunteers and in patients suffering from chronic kidney disease.

Tony Johnson, M.D., President and CEO of Goldfinch Bio, said in a statement that the Phase 1 study will determine the future clinical development route of GFB-887, a developing targeted podocyte-protective therapy for patients suffering from rare glomerular diseases with immense unmet need, and patients with DN, which is the main cause of end-stage kidney disease.

Johnson further claimed that the initiation of this clinical trial is backed by Goldfinch’s recently presented preclinical data showcasing the potential of GFB-887 for ameliorating proteinuric kidney disease through the inhibition of the TRPC5-Rac1 pathway.

According to sources familiar with the trial, the Phase 1 study will be performed in two parts. Part 1 will include a single-ascending dose, escalation component, and a food effect component among healthy participants. Part 2 will comprise multiple ascending dose components among healthy participants. The Phase 1 program will also comprise research on renally-impaired patients, reported sources.

Key study objectives include assessment of the tolerability, safety, and pharmacokinetic profile of single and multiple dosages of GFB-887, while the secondary objective of the trial includes the evaluation of tolerability, safety, and pharmacokinetic profile of GFB-887 in patients suffering from renal impairment.

For the record, the GFB-887 clinical program is backed by preclinical data within multiple models of progressive kidney disorders, including data from organoids and podocytes derived from human stem-cell, recently demonstrated at the 2019 ISN World Congress of Nephrology meeting.

Source Credits: https://www.businesswire.com/news/home/20190606005151/en/Goldfinch-Bio-Initiates-Phase-1-Clinical-Trial

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Change Healthcare acquires innovative technologies provider, PDX
Change Healthcare acquires innovative technologies provider, PDX
By Mateen Dalal

Change Healthcare has recently announced the acquisition of a leading patient-centric & innovati...

Innovent-Eli Lilly and Company announce TYVYT® ORIENT-2 study results
Innovent-Eli Lilly and Company announce TYVYT® ORIENT-2 study results
By Mateen Dalal

Innovent Biologics, Inc. and Eli Lilly and Company have jointly announced the results of the pivotal...

ZALORA-The Trade Desk to collaborate for new measurement capabilities
ZALORA-The Trade Desk to collaborate for new measurement capabilities
By Mateen Dalal

ZALORA, a leading online fashion destination, has reportedly agreed to collaborate with an advertisi...